BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
See today's BioWorld
Home
» Novartis backs Seventure’s €160M venture fund targeting gut microbiome
To read the full story,
subscribe
or
sign in
.
Novartis backs Seventure’s €160M venture fund targeting gut microbiome
Dec. 15, 2015
By
Cormac Sheridan
DUBLIN – Seventure Partners has added Novartis AG as an investor in a new closing of its Health for Life Capital fund, taking the total to €160 million (US$175 million). It’s further evidence that big pharma is taking this emerging sector seriously.
BioWorld